Fate Therapeutics Q2 EPS $(0.54) Beats $(0.59) Estimate, Sales $933.00K Miss $5.53M Estimate
Portfolio Pulse from mahesh@benzinga.com
Fate Therapeutics reported Q2 losses of $(0.54) per share, beating the analyst consensus estimate of $(0.59) by 8.47%. However, the company's quarterly sales of $933.00K missed the analyst consensus estimate of $5.53M by 83.13%, marking a 94.97% decrease from the same period last year.
August 08, 2023 | 8:49 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Fate Therapeutics' Q2 earnings beat estimates but sales significantly missed expectations and decreased YoY.
While Fate Therapeutics beat earnings estimates, the significant miss on sales and the large YoY decrease could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100